Scribd Logo
Upload

Welcome to Scribd!

  • Thyroid Notes

    Uploaded by

    Allyssa Denisse Lozada
    9 views2 pages
    The panel voted to update the NCCN Guidelines for Thyroid Carcinoma to include pralsetinib as a treatment option for patients with RET fusion-positive or RET mutation-positive thyroid cancers based on its FDA approval. This includes papillary carcinoma, follicular carcinoma, Hürthle cell carcinoma, medullary carcinoma, and anaplastic carcinoma. The panel consensus was to designate pralsetinib as a Category 2A preferred systemic therapy option for these patients based on a review of clinical data and references.

    Original Description:

    Original Title

    Thyroid notes

    Copyright

    © © All Rights Reserved

    Available Formats

    PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Report this Document
    The panel voted to update the NCCN Guidelines for Thyroid Carcinoma to include pralsetinib as a treatment option for patients with RET fusion-positive or RET mutation-positive thyroid cancers based on its FDA approval. This includes papillary carcinoma, follicular carcinoma, Hürthle cell carcinoma, medullary carcinoma, and anaplastic carcinoma. The panel consensus was to designate pralsetinib as a Category 2A preferred systemic therapy option for these patients based on a review of clinical data and references.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Flag for inappropriate content
    9 views2 pages

    Thyroid Notes

    Uploaded by

    Allyssa Denisse Lozada
    The panel voted to update the NCCN Guidelines for Thyroid Carcinoma to include pralsetinib as a treatment option for patients with RET fusion-positive or RET mutation-positive thyroid cancers based on its FDA approval. This includes papillary carcinoma, follicular carcinoma, Hürthle cell carcinoma, medullary carcinoma, and anaplastic carcinoma. The panel consensus was to designate pralsetinib as a Category 2A preferred systemic therapy option for these patients based on a review of clinical data and references.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Flag for inappropriate content
    of 2

    NCCN Guidelines for Thyroid Carcinoma V.3.

    2020 – Interim on 12/21/20

    Guideline Page Institution Vote


    Panel Discussion/References
    and Request YES NO ABSTAIN ABSENT
    PAP-10, PAP-11, FOLL-8, FOLL-9, HURT-8, HURT-9 Based on the review of the data in the noted 17 1 5 7
    Internal request: references and the FDA approval, the panel
    In response to the FDA approval of pralsetinib consensus was to include pralsetinib as an option for
    for adult and pediatric patients 12 years of age and patients with RET-fusion positive papillary carcinoma,
    older with advanced or metastatic RET fusion positive follicular carcinoma, or Hürthle Cell Carcinoma who
    thyroid cancer who require systemic therapy and who have structurally persistent/recurrent locoregional or
    are radioactive iodine-refractory (if radioactive iodine is metastatic disease not amenable to radioactive
    appropriate). iodine therapy. The Panel consensus supported a
    category 2A systemic therapy option.
    External request from BluePrint Medicines Corp.
    (12/1/20) to include pralsetinib as a treatment option See Submission for References.
    for:
    • Adult and pediatric patients 12 years of age and older
    with advanced or metastatic RET fusion-positive
    thyroid cancer who require systemic therapy and who
    are radioactive iodine-refractory (if radioactive iodine is
    appropriate).
    MEDU-6 and MEDU-7 Based on the review of the data in the noted 18 1 4 7
    Internal request: references and the FDA approval, the panel
    In response to the FDA approval of pralsetinib consensus was to include pralsetinib as an option for
    for adult and pediatric patients 12 years of age and patients with RET-mutation positive medullary
    older with advanced or metastatic RET-mutant carcinoma who have recurrent or persistent
    medullary thyroid cancer (MTC) who require systemic locoregional or distantly metastatic disease. The
    therapy. Panel consensus supported a category 2A, preferred
    systemic therapy option.
    External request from BluePrint Medicines Corp.
    (12/1/20) to include pralsetinib as a treatment option See Submission for References.
    for:
    • Adult and pediatric patients 12 years of age and older
    with advanced or metastatic RET-mutant medullary
    thyroid cancer (MTC) who require systemic therapy

    ANAP-2 and ANAP-A Based on the review of the data in the noted 15 1 5 9
    Internal request: references and the FDA approval, the panel
    In response to the FDA approval of pralsetinib consensus was to include pralsetinib as an option for
    for adult and pediatric patients 12 years of age and patients with metastatic RET-fusion positive
    older with advanced or metastatic RET fusion positive anaplastic carcinoma. The Panel consensus
    thyroid cancer who require systemic therapy and who supported a category 2A, preferred systemic therapy
    option.
    NCCN Guidelines for Thyroid Carcinoma V.3.2020 – Interim on 12/21/20

    are radioactive iodine-refractory (if radioactive iodine is


    appropriate). The Panel also supported the inclusion of pralsetinib
    to footnote “g” with the reference: Subbiah et al.
    External request from BluePrint Medicines Corp. Clinical activity of the RET inhibitor pralsetinib (BLU-
    (12/1/20) to include pralsetinib as a treatment option 667) in patients with RET fusion positive solid tumors.
    for: Presented at the American Society of Clinical
    • Adult and pediatric patients 12 years of age and older Oncology (ASCO) Annual Meeting; May 29-31,
    with advanced or metastatic RET fusion-positive 2020).
    thyroid cancer who require systemic therapy and who
    are radioactive iodine-refractory (if radioactive iodine is See Submission for References.
    appropriate).

    You might also like